
500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel on March 16-17....

BioNTech bags Instadeep for £562m
According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...

INDUSTRIA BIOTEC 2023 with a broader perspective
At this year's INDUSTRIA BIOTEC – a European industry meeting that took place at the KINDL Centre for Contemporary Art in Berlin at the beginning of...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Evonetix extends Series B financing to US$54m
According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

European VCs join US$105m financing of US Mediar Thx
Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...